Insider Selling: Encompass Health Co. (NYSE:EHC) CFO Sells 12,260 Shares of Stock

Encompass Health Co. (NYSE:EHC) CFO Douglas E. Coltharp sold 12,260 shares of the stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $86.34, for a total value of $1,058,528.40. Following the transaction, the chief financial officer now owns 136,227 shares in the company, valued at approximately $11,761,839.18. The sale was disclosed in a document filed with the SEC, which is available through this link.

Encompass Health Trading Down 0.0 %

EHC stock traded down $0.01 during midday trading on Wednesday, hitting $87.01. 131,007 shares of the company’s stock were exchanged, compared to its average volume of 656,305. Encompass Health Co. has a 1-year low of $57.55 and a 1-year high of $94.38. The company has a current ratio of 1.37, a quick ratio of 1.37 and a debt-to-equity ratio of 1.14. The stock has a market capitalization of $8.76 billion, a PE ratio of 23.52, a P/E/G ratio of 1.45 and a beta of 0.89. The business has a 50-day simple moving average of $86.60 and a two-hundred day simple moving average of $81.88.

Encompass Health (NYSE:EHC) last issued its quarterly earnings data on Monday, August 5th. The company reported $1.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.01 by $0.10. Encompass Health had a return on equity of 18.01% and a net margin of 7.60%. The firm had revenue of $1.30 billion during the quarter, compared to the consensus estimate of $1.30 billion. During the same period last year, the company earned $0.95 EPS. The company’s quarterly revenue was up 9.6% on a year-over-year basis. On average, sell-side analysts predict that Encompass Health Co. will post 4.09 EPS for the current fiscal year.

Encompass Health Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, October 15th. Shareholders of record on Tuesday, October 1st will be given a $0.17 dividend. This is a positive change from Encompass Health’s previous quarterly dividend of $0.15. The ex-dividend date of this dividend is Tuesday, October 1st. This represents a $0.68 dividend on an annualized basis and a yield of 0.78%. Encompass Health’s payout ratio is presently 18.38%.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the company. Principal Securities Inc. purchased a new stake in Encompass Health during the 4th quarter worth approximately $25,000. Benjamin F. Edwards & Company Inc. grew its stake in shares of Encompass Health by 360.2% in the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 405 shares of the company’s stock worth $27,000 after acquiring an additional 317 shares in the last quarter. GAMMA Investing LLC purchased a new stake in shares of Encompass Health during the fourth quarter worth $33,000. Parallel Advisors LLC raised its stake in shares of Encompass Health by 192.3% in the fourth quarter. Parallel Advisors LLC now owns 573 shares of the company’s stock valued at $38,000 after acquiring an additional 377 shares in the last quarter. Finally, Oakworth Capital Inc. purchased a new position in Encompass Health in the second quarter valued at $40,000. 97.25% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have recently issued reports on EHC shares. Raymond James reiterated a “strong-buy” rating and issued a $95.00 target price (up previously from $85.00) on shares of Encompass Health in a research report on Friday, April 26th. Leerink Partnrs upgraded Encompass Health to a “strong-buy” rating in a report on Wednesday, July 10th. Royal Bank of Canada increased their target price on shares of Encompass Health from $83.00 to $95.00 and gave the company an “outperform” rating in a research report on Wednesday, May 22nd. Stephens restated an “overweight” rating and set a $105.00 price target on shares of Encompass Health in a research report on Tuesday, August 6th. Finally, Truist Financial increased their price objective on shares of Encompass Health from $95.00 to $100.00 and gave the company a “buy” rating in a report on Monday, July 15th. Nine investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $99.88.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.